Small cell lung cancer · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Durvalumab monotherapy Variant #01 | — | R 61 460 | 14d | 16.6 mo | 55.9 mo | 37 | R 2 274 035 PFS proxy | 2 |
Cisplatin and Irinotecan (IC) N/A - secondary systemic drug | — | R 743 | 42d | — | ~10.2 mo | — | — | 3 |
Whole brain irradiation N/A - radiation Partial | — | — | 21d | — | 6.7 mo | — | — | 1 |
Observation Partial | — | — | — | — | 16.4 mo | — | — | 1 |
Placebo Partial | — | — | — | 9.2 mo | 33.4 mo | — | — | 2 |
Radiation therapy N/A - radiation Partial | — | — | 49d | ~5.1 mo | ~12.0 mo | ~4 | — | 1 |
6 of 6 regimens shown